Form 4: Kineta Director Raymond Bartoszek Reports Significant Stock Transactions and Option Vesting Post-Merger Approval

Kineta, Inc. Director Raymond J. Bartoszek has reported recent stock acquisitions, dispositions, and the full vesting of stock options following the company's merger agreement approval.

Summary

• Raymond J. Bartoszek, a Director of Kineta, Inc. (KANT), reported several transactions involving the company's common stock.
• On June 23, 2025, Mr. Bartoszek acquired 12,500 shares of common stock through the exercise of stock options at an exercise price of $0.611 per share.
• Concurrently on June 23, 2025, he disposed of 4,706 shares of common stock at $0.26 per share, likely to cover the exercise price or tax liabilities (indicated by transaction code 'F').
• On June 25, 2025, Mr. Bartoszek acquired an additional 6,000 shares of common stock at a price of $0.00 per share, indicating a grant or award.
• Following these transactions, Mr. Bartoszek directly beneficially owns 31,000 shares of Kineta Common Stock.
• His indirect beneficial ownership includes 1,748,473 shares held by RLB Holdings Connecticut, LLC, where he is a managing member, and 1,001 shares held by his son, and 1,000 shares held by his daughter.
• The stock options, with an exercise price of $0.611 and an expiration date of September 3, 2034, became fully vested on June 23, 2025.
• This vesting was pursuant to an Optionholder Treatment Agreement dated June 16, 2025, and the Agreement and Plan of Merger dated December 11, 2024 (amended May 5, 2025), which was approved by Kineta's stockholders on June 23, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a positive event for the director, Raymond J. Bartoszek, with the full vesting of his stock options and a net increase in his direct beneficial ownership. These transactions are directly linked to the approval of a significant merger agreement, suggesting strategic progress for Kineta, Inc.

Positives

• Full vesting of 12,500 stock options on June 23, 2025, indicating a positive event for the option holder.
• Acquisition of 6,000 shares at $0.00, suggesting a grant or award, which increases direct ownership without cost.
• The net effect of the reported transactions is an increase in direct beneficial ownership from 25,000 shares to 31,000 shares.
• The approval of the merger agreement by stockholders on June 23, 2025, which triggered the option vesting, indicates progress on a strategic corporate action.

Negatives

• Disposition of 4,706 shares of common stock on June 23, 2025, at $0.26 per share, which reduces direct ownership, likely for tax purposes or to cover exercise costs.

Future Outlook

NA

Industry Context

This Form 4 filing details insider transactions for Kineta, Inc., a biotechnology company. While the filing itself is specific to an individual's stock movements, the underlying event of the merger agreement approval with TuHURA Biosciences, Inc. suggests a strategic consolidation within the biotech sector, potentially aimed at combining pipelines or resources. Such mergers are a common trend in the industry for growth and efficiency.

Corporate Governance

Related Party Transactions

• Raymond J. Bartoszek's indirect beneficial ownership includes 1,748,473 shares held by RLB Holdings Connecticut, LLC, where he is a managing member and shares voting and dispositive power. This constitutes a related party holding.

Stakeholder Impact

• Shareholders: The approval of the merger agreement, which triggered the option vesting, could be seen as a positive step towards strategic growth or consolidation, potentially impacting future share value. Insider acquisitions can sometimes signal confidence.
• Employees: The merger agreement and option treatment agreement could have implications for employee equity plans and overall company structure post-merger.
• Management/Directors: The vesting of options and subsequent transactions directly impact the compensation and equity holdings of the reporting director.

Next Steps

• The approval of the Agreement and Plan of Merger by stockholders on June 23, 2025, implies that the merger process between Kineta, Inc. and TuHURA Biosciences, Inc. will proceed as outlined in the agreement.

Key Dates

Keywords

Kineta Inc., KANT, SEC Form 4, insider trading, stock options, beneficial ownership, director transactions, equity incentive plan, merger agreement, TuHURA Biosciences